|
Friday, May 30, 2025, Chicago, Illinois, 11:15 AM – 12:45 PM Central Time (12:15 PM – 1:45 PM Eastern Time)
Data + Perspectives: Clinical Investigators Discuss the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates in Lung CancerA CME Symposium Held in Conjunction with the 2025 ASCO® Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, Illinois Phone: (312) 922-4400 Program Schedule — Central Time 11:00 AM – 11:15 AM — Registration 11:15 AM – 12:45 PM — Educational Lunch Meeting Meeting Room Continental Room A&B (Lobby Level) Faculty
Marina Chiara Garassino, MBBS Section of Hematology/Oncology Professor of Medicine Director, Thoracic Oncology Program Department of Medicine The University of Chicago Chicago, Illinois John V Heymach, MD, PhD Professor and Chair Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Professor Solange Peters, MD, PhD Medical Oncology Director Lausanne University Hospital Lausanne, Switzerland
Moderator
Jacob Sands, MD Physician Dana-Farber Cancer Institute Assistant Professor Harvard Medical School Boston, Massachusetts This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Program Schedule — Central Time
11:00 AM – 11:15 AM — Registration 11:15 AM – 12:45 PM — Educational Lunch Meeting Topics to Be Discussed
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Prof Peters — Advisory Committees and Consulting Agreements (All Fees to Institution): AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BerGenBio ASA, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm, Foundation Medicine, F-star Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, HUTCHMED, Illumina, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck Serono, Merrimack Pharmaceuticals Inc, Mirati Therapeutics Inc, MSD, Novartis, Novocure Inc, Nykode Therapeutics, Pfizer Inc, PharmaMar, Promontory Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Takeda Pharmaceutical Company Limited; Contracted Research (Institutional Support): Principal investigator for trials sponsored by Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, iTeos Therapeutics, Mirati Therapeutics Inc, MSD, PharmaMar, Promontory Therapeutics, Seagen Inc; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Speakers Bureaus (All Fees to Institution): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Foundation Medicine, Genentech, a member of the Roche Group, GSK, Illumina, Ipsen Biopharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited. Additional faculty to be announced. MODERATOR — Dr Sands — Data and Safety Monitoring Board: Johnson & Johnson Pharmaceuticals; Grant/Research Funding: Harpoon Therapeutics, Novartis; Honoraria for Consulting: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Curadev, Daiichi Sankyo Inc, G1 Therapeutics Inc, Gilead Sciences Inc, Lilly, Medtronic Inc, Merck, PharmaMar, Sanofi. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. Hilton Chicago
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the 2025 ASCO® Annual Meeting. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event. Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation. |